Examining Data from MonumenTAL-2 Study

EP: 1.Unmet Needs and Treatment Approaches in Newly Diagnosed Multiple Myeloma

EP: 2.ASH 2023: PERSEUS Trial Overview

EP: 3.Considerations for Combination Therapy and MRD Testing in Newly Diagnosed Multiple Myeloma Patients

EP: 4.ASH 2023: Analyzing IsKia Trial

Now Viewing

EP: 5.Examining Data from MonumenTAL-2 Study

EP: 6.Optimizing Bispecific Use in Multiple Myeloma Treatment

EP: 7.Navigating Impact of RRMM Treatment on Patient Quality of Life

EP: 8.Key RRMM-Related Takeaways from ASH 2023

This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.

The phase 1/2 MonumenTAL-2 study evaluated the combination of the anti-GPRC5D antibody talquetamab and the immunomodulatory drug pomalidomide in relapsed/refractory multiple myeloma. Patients had received a median of 3 prior lines of treatment. Pomalidomide was started at the lower dose of 2 mg (range, 2-4 mg) to manage myelosuppression risks. Stepwise talquetamab dose increases also occurred. Despite some dose reductions, adverse reactions were consistent with each agent’s known single-agent toxicities.

The overall response rate was 94% with talquetamab 0.4 mg/kg weekly, on par with other antibody combinations like talquetamab plus teclistamab. Deep responses occurred, with 44% stringent complete response rate and 63% complete response rate in heavily pretreated patients. Although next steps for talquetamab are still unknown, this data supports continued development of GPRC5D-targeting combinations in myeloma.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.